Pricing above its range an upsized number of shares, Braveheart Bio Inc. – a company that began operations just last year – raised $382.5 million in its IPO to advance into phase III trials lead candidate BHB-1893 for obstructive and non-obstructive hypertrophic cardiomyopathy (HCM).